Thrombolytic treatment of occluded central venous access devices including those used for haemodialysis The 2 mg vial is the only recommended presentation of alteplase for use in this indication.
Genentech recently initiated the Phase III TIMELESS trial to evaluate TNKase (tenecteplase) in people with acute ischemic stroke (AIS) when...